|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2000-2-16
|
|
pubmed:abstractText |
Anthracyclines are among the most active drugs in the treatment of breast carcinoma and exhibit a steep dose-response curve in vitro. This trial was performed to determine the efficacy and toxicity of epirubicin in the treatment of patients with advanced breast carcinoma when administered as a single agent in maximal doses.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2000 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
88
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
375-80
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:10640971-Adult,
pubmed-meshheading:10640971-Aged,
pubmed-meshheading:10640971-Antibiotics, Antineoplastic,
pubmed-meshheading:10640971-Breast Neoplasms,
pubmed-meshheading:10640971-Epirubicin,
pubmed-meshheading:10640971-Female,
pubmed-meshheading:10640971-Humans,
pubmed-meshheading:10640971-Infusions, Intravenous,
pubmed-meshheading:10640971-Middle Aged,
pubmed-meshheading:10640971-Neutropenia,
pubmed-meshheading:10640971-Treatment Outcome,
pubmed-meshheading:10640971-Ventricular Function, Left
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
A phase II trial of high dose epirubicin in patients with advanced breast carcinoma.
|
|
pubmed:affiliation |
Division of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, Indiana.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase II
|
